Vertex Pharmaceuticals Raises FY24 Revenue Guidance From $10.55B-$10.75B To $10.65B-$10.85B Vs $10.76B Est.
Portfolio Pulse from Benzinga Newsdesk
Vertex Pharmaceuticals has raised its FY24 revenue guidance from $10.55B-$10.75B to $10.65B-$10.85B, citing growth in CF and the launch of CASGEVY®. The company also provided updated guidance on R&D and SG&A expenses, including costs related to the Alpine acquisition.
August 01, 2024 | 8:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vertex Pharmaceuticals has increased its FY24 revenue guidance to $10.65B-$10.85B, driven by growth in CF and the launch of CASGEVY®. The company also updated its R&D and SG&A expenses, factoring in the Alpine acquisition.
The increase in revenue guidance and the detailed update on expenses, including the impact of the Alpine acquisition, are positive indicators for Vertex Pharmaceuticals. This suggests strong performance and strategic investments, likely boosting investor confidence and short-term stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100